Celltrion Inc Total Liabilities
Celltrion Inc total liabilities. Based on the latest financial reports, Celltrion Inc (068270) has total liabilities worth ₩5.65 Trillion KRW (≈ $3.83 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Celltrion Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Celltrion Inc (2007–2025)
Total liabilities of Celltrion Inc from 2007 to 2025. This chart illustrates how Celltrion Inc's total liabilities have evolved over time, based on quarterly financial data. Check Celltrion Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Celltrion Inc Competitors by Total Liabilities
The table below lists competitors of Celltrion Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bajaj Auto Limited
NSE:BAJAJ-AUTO
|
India | Rs369.77 Billion |
|
Yuanta Financial Holdings Co Ltd
TW:2885
|
Taiwan | NT$3.74 Trillion |
|
Extra Space Storage Inc
NYSE:EXR
|
USA | $14.89 Billion |
|
STMicroelectronics NV ADR
NYSE:STM
|
USA | $6.96 Billion |
|
Flex Ltd
F:FXI
|
Germany | €16.92 Billion |
|
Montage Technology Co Ltd
SHG:688008
|
China | CN¥1.74 Billion |
|
WUS Printed Circuit Kunshan Co Ltd
SHE:002463
|
China | CN¥12.31 Billion |
|
Alcon AG
SW:ALC
|
Switzerland | CHF9.51 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Celltrion Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Celltrion Inc.
Liquidity & Leverage Metrics
Celltrion Inc Total Liabilities Ratios Explained
Celltrion Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celltrion Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celltrion Inc (2007–2025)
The table below shows the annual total liabilities of Celltrion Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩4.98 Trillion ≈ $3.38 Billion |
+43.37% |
| 2024-12-31 | ₩3.48 Trillion ≈ $2.36 Billion |
+24.48% |
| 2023-12-31 | ₩2.79 Trillion ≈ $1.89 Billion |
+72.60% |
| 2022-12-31 | ₩1.62 Trillion ≈ $1.10 Billion |
-0.39% |
| 2021-12-31 | ₩1.62 Trillion ≈ $1.10 Billion |
+1.96% |
| 2020-12-31 | ₩1.59 Trillion ≈ $1.08 Billion |
+61.40% |
| 2019-12-31 | ₩986.73 Billion ≈ $668.70 Million |
+8.69% |
| 2018-12-31 | ₩907.85 Billion ≈ $615.24 Million |
+2.74% |
| 2017-12-31 | ₩883.60 Billion ≈ $598.80 Million |
+7.37% |
| 2016-12-31 | ₩822.97 Billion ≈ $557.72 Million |
-12.30% |
| 2015-12-31 | ₩938.39 Billion ≈ $635.93 Million |
-3.72% |
| 2014-12-31 | ₩974.60 Billion ≈ $660.48 Million |
+9.34% |
| 2013-12-31 | ₩891.38 Billion ≈ $604.07 Million |
+30.55% |
| 2012-12-31 | ₩682.77 Billion ≈ $462.70 Million |
+34.46% |
| 2011-12-31 | ₩507.77 Billion ≈ $344.11 Million |
+35.20% |
| 2010-12-31 | ₩375.57 Billion ≈ $254.52 Million |
+37.31% |
| 2009-12-31 | ₩273.53 Billion ≈ $185.37 Million |
-2.15% |
| 2008-12-31 | ₩279.55 Billion ≈ $189.45 Million |
+701.67% |
| 2007-12-31 | ₩34.87 Billion ≈ $23.63 Million |
-- |
About Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for … Read more